Webinar | November 23, 2021

Leveraging Lessons From The COVID-19 Pandemic To Accelerate The Development And Production Of Viral-Based Gene Therapies

Source: Cytiva

While there are currently over 1400 clinical cell and gene therapy programs, trial recruitment, raw material supply chains, and low-yield processes are just some of the multiple challenges facing the industry. The recent pandemic revealed that with the proper framework, a drug product can be developed, clinically tested, and produced for hundreds of millions of patients in less than a year. What lessons can we apply from this effort for AAV development and production? How can we rethink regulatory filing strategy? And why does the cell and gene therapy arena so urgently need these learnings?

VIEW THE WEBINAR!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of BioProcess Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: